Mometasone
- Generic Name
- Mometasone
- Brand Names
- Asmanex, Dulera, Elocom, Elocon, Nasonex, Ryaltris, Sinuva, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30Cl2O6
- CAS Number
- 83919-23-7
- Unique Ingredient Identifier
- 04201GDN4R
- Background
Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as well. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its ...
- Indication
Inhaled mometasone furoate is indicated for prophylaxis of asthma in patients ≥4 years. Applied topically as an ointment, mometasone furoate is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years.
...
- Associated Conditions
- Asthma, Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Dermatitis, Dermatitis, Eczematous caused by superficial Fungal skin infection, Moderate to Severe Plaque Psoriasis, Pruritus, Psoriasis, Psoriasis, Moderate to Severe, Seasonal Allergic Rhinitis, Seasonal Allergies, Skin Diseases, Eczematous, Skin Infections, Moderate, severe Seasonal Allergic Rhinitis, Ocular effects
- Associated Therapies
- -
Study of CRx-191 to Assess Activity in Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- Zalicus
- Target Recruit Count
- 20
- Registration Number
- NCT00557739
- Locations
- 🇩🇪
bioskin GmbH, Berlin, Germany
Phase I Study of Topical CRx-191 in Normal Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2007-11-15
- Lead Sponsor
- Zalicus
- Target Recruit Count
- 20
- Registration Number
- NCT00544687
- Locations
- 🇩🇪
bioskin GmbH, Hamburg, Germany
A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 33
- Registration Number
- NCT00461812
- Locations
- 🇺🇸
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 426
- Registration Number
- NCT00453063
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
- Conditions
- Interventions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- North Central Cancer Treatment Group
- Target Recruit Count
- 176
- Registration Number
- NCT00438659
- Locations
- 🇺🇸
Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
🇺🇸Rush-Copley Cancer Care Center, Aurora, Illinois, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
Study of Mometasone Furoate/Formoterol Fumarate Inhalation Combination in Healthy Volunteers
- Conditions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00418509
- Locations
- 🇬🇧
Novartis, Horsham, United Kingdom
Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 17
- Registration Number
- NCT00361439
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Long Term Safety Of GW685698X Via Nasal Biopsy
- Conditions
- Interventions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 125
- Registration Number
- NCT00224523
- Locations
- 🇳🇱
GSK Investigational Site, Nijmegen, Netherlands
Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
- Conditions
- Interventions
- First Posted Date
- 2003-10-10
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 188
- Registration Number
- NCT00070707
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.